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Introduction
Small noncoding microRNAs (miRNAs) are important both as key pathogenic regulators (1, 2) and as 
biomarkers of  renal disease (3). Their capacity to drive renal disease has now been recognized and begun to 
be translated from preclinical studies (4, 5) to clinical trials of  miRNA inhibitor–based (anti-miR) therapies 
in renal disease (6). The ability of  miRNAs to be stably detected in samples, including urine and serum, 
makes them attractive biomarkers, offering the potential to provide a real-time reflection of  the molecular 
and pathological landscape of  the kidney, without the need for renal biopsy.
With the advent of  microarray and later small RNA-sequencing (sRNA-seq), the bulk tissue transcrip-
tome-wide profile of  miRNAs has been characterized across various renal conditions (7–12). However, 
the expression of  a given miRNA in such whole-tissue transcriptomics reflects both the abundance of  that 
miRNA in each cell type and the proportion of  that cell type within the sample (13). This is problematic 
both for disease process and for biomarker research, as the proportion of  each renal cell type may vary 
considerably among renal health, injury, and repair. For example, it is evident that inflammatory renal 
disease induces a large increase in the ratio of  inflammatory cells to tubular cells as compared with that in 
a healthy kidney (14, 15).
Unlike analysis of gene expression (13), defining cell-specific miRNA expression within the kidney is ham-
pered by the lack of equivalent single-cell sequencing methodology for miRNAs. Although “kidney-enriched” 
miRNAs, such as miR-192, miR-194, and the miR-30 family, have been identified by sRNA-Seq across mul-
tiple organs (16, 17), there are shortcomings to this approach. First, it is unable to detect differences between 
cell types in the kidney, essential for the unambiguous interpretation of a biopsy, for example. Second, it rests 
on the assumption that cell enrichment remains stable across injury and repair. SRNA-Seq to detect the dif-
ferentially expressed miRNAs (DEmiRNAs) in microdissected proximal tubules and glomeruli has provided 
Small noncoding RNAs, miRNAs (miRNAs), are emerging as important modulators in the 
pathogenesis of kidney disease, with potential as biomarkers of kidney disease onset, progression, 
or therapeutic efficacy. Bulk tissue small RNA-sequencing (sRNA-Seq) and microarrays are widely 
used to identify dysregulated miRNA expression but are limited by the lack of precision regarding 
the cellular origin of the miRNA. In this study, we performed cell-specific sRNA-Seq on tubular 
cells, endothelial cells, PDGFR-β+ cells, and macrophages isolated from injured and repairing 
kidneys in the murine reversible unilateral ureteric obstruction model. We devised an unbiased 
bioinformatics pipeline to define the miRNA enrichment within these cell populations, constructing 
a miRNA catalog of injury and repair. Our analysis revealed that a significant proportion of cell-
specific miRNAs in healthy animals were no longer specific following injury. We then applied this 
knowledge of the relative cell specificity of miRNAs to deconvolute bulk miRNA expression profiles 
in the renal cortex in murine models and human kidney disease. Finally, we used our data-driven 
approach to rationally select macrophage-enriched miR-16-5p and miR-18a-5p and demonstrate 
that they are promising urinary biomarkers of acute kidney injury in renal transplant recipients.
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information on the cell-specific miRNA changes in diabetic nephropathy, IgA nephropathy, and focal segmen-
tal glomerulosclerosis (FSGS) (18). Although the most highly expressed miRNAs are listed in both proximal 
tubules and glomeruli, this does not equate to cell selectivity of these miRNAs. Moreover, the DEmiRNAs 
described, while undoubtedly important, may be masked when examining a whole-tissue biopsy sample.
Understanding the cell-specific miRNA expression in the kidney is essential, both to contextualize 
whole-tissue miRNA changes and to identify miRNAs that may have potential utility as either therapeutic 
targets or biomarkers. Because only the most abundant miRNAs in a cell are thought to mediate mRNA 
target suppression (19), profiling the cellular miRNA expression may guide researchers as to which miR-
NAs to mechanistically interrogate and in which cell type. Similarly, this knowledge may enhance the ratio-
nal selection of  biomarkers in kidney disease, based on the expected cellular pathology of  the condition.
To address this knowledge gap, we performed sRNA-Seq on discrete renal cell populations obtained 
from mouse kidney in health, following injury, and during repair. The aim of  the study was to identify 
miRNAs that stringently remained enriched in specific cell types across acute injury, late injury, and repair 
in the kidney, which could be reasonably applied as cell-enriched markers in both acute kidney injury and 
chronic kidney disease. For our analysis pipeline, we combined an unbiased clustering approach and val-
idated it with a supervised methodology, identifying cell-specific miRNAs in the kidney and creating an 
interactive platform for others to explore these results and contextualize their own findings. We then use 
this knowledge to deconvolute DEmiRNA expression in whole-tissue data obtained from a further mouse 
model of  renal injury and in data sets from human renal disease. Finally, we apply this knowledge to ratio-
nally select miRNAs having potential as disease biomarkers, identifying macrophage-enriched miR-18a-5p 
and miR-16-5p as urinary biomarkers of  acute kidney injury following transplantation.
Results
Reversible unilateral ureteric obstruction model induces kidney injury followed by resolution. The reversible unilat-
eral ureteric obstruction (R-UUO) model (20–22) allowed us to map renal miRNA expression in normal, 
injured, and repairing kidney tissue (Figure 1A). One week following UUO, there was widespread renal 
tubular dilatation (Figure 1B) and a marked increase in tubular expression of  kidney injury molecule-1 
(KIM-1) encoded by the gene Havcr1 (Figure 1, B and C). Following reimplantation of  the ureter to reverse 
obstruction, there was a reduction in tubular dilatation and a significant decline in KIM-1 expression, with 
an 83% reduction in Havcr1 expression by 2 weeks of  reversal of  the injury (P < 0.0001 vs. UUO-7), indi-
cating effective reversal of  obstructive tubular injury (Figure 1, B and C).
The kidney is a complex organ with multiple cell types. In order to identify cell-selective miRNAs, we 
chose to examine the sRNA profile of 4 of the key cell types implicitly involved in kidney injury and repair. We 
used FACS of digested cortical kidney tissue to isolate endothelial cells (ECs; CD45–CD31+), F4/80hi macro-
phages (Macs; CD45+F4/80hi), PDGFR-β+ stromal cells/fibroblasts (CD45–CD31–), and proximal tubular cells 
(PT cells; CD45–CD31–LTL+) (Figure 1D). During injury (UUO), the proportion of live PT cells significantly 
decreased, whereas the proportion of CD45+ immune cells, macrophages, and PDGFR-β+ cells significantly 
increased (Figure 1E). Upon reversal, there was significant reduction in the proportion of macrophages but a 
persistence of CD45+ cells, which likely reflects T cell presence during the repair phase as has been observed 
before (22, 23). An increase in ECs with injury was noted; this may be a consequence of increased expression 
of CD31 upon endothelial activation and/or increased liberation of ECs from injured tissue. To assess the 
purity of our populations, we demonstrated that marker gene expression was specific to the corresponding 
cell population (Supplemental Figure 1A; supplemental material available online with this article; https://doi.
org/10.1172/jci.insight.140399DS1).
We performed sRNA-Seq on each of  the isolated cell types from sham-operated animals, at 2 and 7 days 
after UUO (UUO-2, UUO-7) and at 2 weeks following R-UUO (n = 4 per group). Small RNAs were anno-
tated to miRBase and miRNA expression was analyzed. Following quality control (Supplemental Figure 
1B), our initial unbiased clustering demonstrated that the key variance within the miRNA expression data 
was due to cell type rather than the experimental condition, with the least variance observed between the 
endothelial and PDGFR-β+ cells (Figure 1F).
Identification of  cell-selective, consistently enriched miRNAs in the mouse kidney. With this knowledge, we 
then identified cell type–specific miRNA clusters in the different experimental conditions (Figure 2A and 
Supplemental Figures 2–5). First, we performed unsupervised, unbiased fuzzy clustering of  data from each 
time point using mFuzz (ref. 24, Figure 2A, and Supplemental Figures 2–5). Because we knew the cellular 
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Figure 1. R-UUO model induces kidney injury followed by resolution. (A) Schematic of the experimental process. Injury was induced by 2 or 7 days of UUO. After 7 
days of UUO, ureteric reimplantation facilitates reversal of obstruction. At each time point proximal tubular cells, macrophages, endothelial cells, and PDGFR-β+ cells 
were isolated by fluorescence-activated cell sorting (FACS) for small RNA-sequencing (sRNA-Seq). (B and C) By UUO-7 there were marked tubular dilatation (arrows), 
cellular infiltration and increased tubular expression of kidney injury marker-1 (KIM-1/Havcr1) (arrows). Upon reversal (R-UUO), there was a rapid decline in Havcr1 
expression, indicating successful reversal of renal tubular injury. Scale bar: 50 μm. Data shown as mean ± SEM. One-way ANOVA with Tukey’s multiple-compari-
son test. ****P < 0.0001. (D) The renal cortex was digested into single cells, which were separated by FACS into endothelial cells (ECs) (CD45–CD31+), macrophages 
(CD45+F4/80hi), proximal tubular cells (PT cells) (CD45–CD31–LTL+), and PDGFR-β+ (CD45–CD31–PDGFR-β+) cells. (E) The proportions of these sorted cell populations 
varied with injury and repair (n = 4 per group). Data presented as mean ± SD analyzed by Welch’s ANOVA test with Dunnett’s multiple-comparison test. *P < 0.05, 
**P < 0.01, ***P < 0.001, ****P < 0.0001. (F) Principal component analysis of sRNA-Seq data demonstrates that cell type accounts for the key variance in miRNA 
expression (top 500 most variant miRNAs shown, 64 samples). UUO-2, UUO cull day 2; UUO-7, UUO cull day 7; R-UUO, cull following 2 weeks’ reversal of UUO.
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origin of  our samples a priori, we were able to combine this unsupervised approach with filtering by the rel-
ative expression for each miRNA within each cell type, enhancing the stringency of  our selected enriched 
miRNAs. We defined those miRNAs with relatively higher expression (mean cell type z score > 1.15) as 
enriched (Supplemental Figure 6). The 2 approaches demonstrated significant overlap and, taking forward 
those that replicated across both approaches, we identified miRNAs enriched in each cell type for each 
experimental condition: sham (n = 313), UUO-2 (n = 282), UUO-7 (n = 330), and R-UUO (n = 232) (Table 
1 and Supplemental Figure 6).
Organ atlas studies to date have primarily been performed on healthy animals, with the assumption 
that reported cell-specific miRNAs will remain enriched, despite transcriptional changes occurring during 
injury and repair, and thus represent consistent cell markers (25). We demonstrate that across the cell types, 
only 129 out of  408 (31.6%) miRNAs maintain consistent cell-specific enrichment at all time points (Table 
1). On profiling the trajectory of  sham-enriched miRNAs, it could be observed that with injury and repair a 
significant proportion either was no longer cell specific or became enriched in another cell type completely 
(Figure 2B). Importantly, this may confound the interpretation of  their expression in whole-tissue RNA 
data sets of  uninjured tissue.
On unsupervised reclustering of  the data, it was evident that miRNAs exhibiting consistent cell-specific 
enrichment throughout all 4 experimental conditions had superior matching to their corresponding origin 
cell type (Figure 2C). As such, we defined miRNAs enriched in only 1 cell type and at 1, 2–3, and all 4 time 
points as having low (n = 134), moderate (n = 145), and high (n = 129) enrichment consistency, respectively. 
These highly enriched miRNAs (Figure 3), which appeared to be most consistently specific for each cell 
type, were taken forward for downstream analysis and deconvolution of  bulk samples. The enrichment and 
dynamic changes of  all profiled miRNAs can be explored in our interactive online platform available at 
http://www.kidney-enriched-micrornas.com.
Deconvolution of  whole-kidney tissue sRNA-Seq data. The R-UUO model exhibits increased inflammatory 
cell numbers and a loss of  healthy proximal tubules with injury, with partial recovery in R-UUO (Figure 
1, B and E), as we have previously described (22). We set out to explore whether the expression changes in 
whole-tissue sRNA-Seq of  our highly enriched miRNAs mirrored the changes in the proportions of  renal 
cells determined by flow cytometry. This would allow us to better contextualize changes in whole-kidney 
miRNA expression, applicable to a typical renal biopsy.
To interrogate this, we first plotted the change in expression between experimental time points of  the 
highly enriched miRNAs in each cell type in the whole-tissue sRNA-Seq data from the R-UUO model and 
compared this with that of  nonenriched miRNAs. No overall shift in the expression of  nonenriched miR-
NAs was observed between any of  the experimental conditions, with the proportion of  upregulated and 
downregulated miRNAs evenly distributed across the central axes (purple line, Figure 4A and Supplemen-
tal Figure 7). With early injury (sham vs. UUO-2), there was a loss of  PT-enriched miRNAs, which became 
more marked by UUO-7 (blue line). As the injury progressed (UUO-7), there was a significant increase in 
the macrophage-enriched miRNAs (green line) versus both sham and UUO-2. In addition, PDGFR-β+–
enriched miRNAs were upregulated at UUO-7, when established fibrosis was evident (red line). There 
were no significant changes in enriched and nonenriched miRNA expression between UUO-7 and R-UUO. 
Volcano plots displaying the profile of  enriched cells for all experimental data sets and comparisons are 
available to visualize at http://www.kidney-enriched-micrornas.com.
The global expression profiles of  our cell-enriched miRNAs mirrored the changes observed in cellular 
proportions on flow cytometry (Figure 1E); for example, with injury, we observed an increase in macro-
phages (CD45+F4/80hi) and PDGFR-β+ cells, alongside an early and sustained loss of  PT cells.
Within each cell type we identified that several miRNAs exhibited dynamic miRNA expression with 
injury and repair (Table 2). The expression profile of  each individual miRNA can be explored at http://
www.kidney-enriched-micrornas.com. We also observed dynamic expression in the enriched miRNA pop-
ulation (Figure 3). For example, within the individual cell populations we found that in the PDGFR-β+ 
cells during late injury, there was substantial loss of  enriched miR-143 and -145 and a significant increase in 
miR-199 and -214 (Supplemental Figure 8). We and others have previously shown that miR-214 is involved 
in renal injury and fibrosis (1, 26–28).
We next wished to determine whether the changes in the expression of  enriched miRNAs over time 
within the bulk sRNA-Seq are due to differential expression of  those miRNAs within each cell type or 
reflect changes in the proportion of  cell types at each time point. We directly compared the expression 
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Figure 2. Development of kidney cell enrichment clusters. Analysis of single population sRNA-Seq of macrophage (Mac; n = 16), endothelial (EC; n = 16), 
PDGFR-β+ (n = 15), and proximal tubular (PT; n = 16) sorted cells (n = 3–4 per time point) from the R-UUO model to identify miRNAs specific for each cell 
type. (A) For each time point, cell clusters were developed using a combination of unbiased fuzzy clustering (mFuzz) and filtering relative expression (z 
score) in each cell type (abbreviated example shown of UUO-2, full data Supplemental Figures 2–5). (B) Sankey plot showing the trajectory of each individ-
ual miRNA enriched at baseline (Sham). Many miRNAs either became non–cell specific or occasionally switched cell type enrichment during renal injury 
and repair. (C) On unsupervised clustering, miRNAs in high enrichment consistency clusters were noted to have greater cell specificity when mapped to all 
time points. Heatmap: Each row represents a miRNA; each column is a sample, with clustering by Euclidian distances. UUO, unilateral ureteric obstruction; 
R-UUO, reversal of UUO (2 weeks’ reversal); PGF/PDGFR-β, platelet-derived growth factor receptor–β.
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changes in the bulk (cortical) and isolated macrophage sRNA-Seq data sets. While the expression of  mac-
rophage-enriched miRNAs increased with injury in the bulk sRNA-Seq data (orange); no increase was 
observed within the macrophages themselves (blue) (Figure 4B and Supplemental Figure 9A). Thus, the 
observed changes in the enriched miRNAs in the bulk sRNA-Seq are likely a consequence of  either an 
influx of  monocytes transitioning to F4/80hi macrophages or proliferation of  resident macrophages skew-
ing the sample cellular composition in the kidney.
In the PT cells, there was downregulation in the expression of  PT-enriched miRNAs with injury in 
both the whole-tissue (orange) and to a lesser extent within PT cells (blue) (Figure 4C and Supplemental 
Figure 9B). Upon reversal, there was a relative upregulation of  PT cell–enriched miRNAs within the proxi-
mal tubular cells that was not evident within the whole-tissue sample. This would suggest changes observed 
in PT cell–enriched miRNAs on the whole-tissue sample may be in part compositional but are also related 
to downregulation of  miRNA expression within the proximal tubular cells due to dedifferentiation during 
injury. Contrastingly, within the PDGFR-β+ cells, there was a large transcriptional increase of  PDGFR-β+–
enriched miRNAs, outstripping the measurable signal within the whole-tissue data set (Supplemental Fig-
ure 10A). Endothelial enriched miRNAs remained relatively stable in ECs and within the whole-tissue data 
set (Supplemental Figure 10B).
Taken together, this suggested these cell-enriched miRNAs could be used as a window to understand 
the cellular landscape in the injured and repairing kidney.
MiRNAs are well conserved across phyla (29) and as such we next sought to assess whether the 
enriched miRNAs were also informative in murine and human acute kidney injury. We selected mac-
rophage-enriched miR-18a-5p and miR-16-5p and PT cell–enriched miR-194-5p as they all demon-
strated high cell-specific enrichment (Figure 5A). We confirmed their cellular localization in the 
R-UUO model by in situ hybridization, demonstrating that miR-194-5p was expressed predominantly 
in tubules while miR-16-5p and miR-18a-5p were expressed in the interstitium (Figure 5B). Two of  
these miRNAs, miR-18a-5p and miR-194-5p, also demonstrated early dynamic differential expression 
in response to injury and repair in the R-UUO model (Figure 5C) and correlated well with their cor-
responding cell number on flow cytometry (Figure 5C). MiR-16-5p was selected because it had stable 
expression regardless of  injury, suggesting that the changes in miR-16-5p observed in bulk renal tissue 
may be more reflective of  macrophage number (Figure 5C).
To gain insight into the potential biological pathways influenced by the dynamic expression of  miR-
18a-5p and miR-194-5p, we determined the validated targets (Supplemental Table 1. We then cross-ref-
erenced the list of  validated targets with expression data from single-cell RNA-sequencing (scRNA-se-
quencing) performed in the same model (22) and looked for targets for which the gene expression was 
inversely correlated with miRNA expression. This analysis revealed that for macrophage-derived miR-
18a-5p several targets were involved in the cell cycle, e.g., Ccnd1 (Supplemental Figure 11), and TGF-β 
signaling, e.g., Tgfbr1. Tgfbr1 signaling has been shown to be critical for functional specification in 
intestinal macrophages (30). For miR-194-5p targets included Runx1 (Supplemental Table 1), which has 
been shown to be upregulated in renal injury and to be targeted by 194-5p (31, 32).
Table 1. MiRNA enrichment consistency
Enrichment Low Moderate Moderate High All
(Experimental points) (1) (2) (3) (4) (1–4)
Cell type Number of enriched 
MiRNAs (row-wise %)
Total
Macrophage (F4/80hi) 40 (26.8%) 27 (18.1%) 21 (14.1%) 61 (40.9%) 149
Proximal tubular (LTL+) 40 (30.1%) 36 (27.1%) 26 (19.5%) 31 (23.3%) 133
PDGFR-β+ 19 (30.2%) 9 (14.3%) 16 (25.4%) 19 (30.1%) 63
Endothelial (CD31+) 35 (55.5%) 6 (9.52%) 4 (6.35%) 18 (28.6%) 63
All cells 134 (16.4%) 78(19.1%) 67(32.8%) 129(31.6%) 408 
The number of miRNAs maintaining cell-specific enrichment for cell type is shown. Only 31.6% of miRNAs maintained enrichment in all 4 
experimental conditions. MiRNAs enriched at 1, 2–3, and 4 out of the 4 conditions studied were grouped as having low, moderate, or high enrichment 
consistency, respectively.
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To assess if  the renal expression of  these miRNAs was conserved across renal injury stimuli, we 
employed a mouse model of  ischemia/reperfusion injury (IRI). Following 18 minutes of  unilateral renal 
artery occlusion, the IRI animals demonstrated significant early acute tubular necrosis (ATN), macrophage 
infiltration, and ultimately progression to fibrosis (Figure 6, A–C). CD68 was used as a macrophage mark-
er, and the staining was positive in the interstitium (Figure 6C), in areas overlapping with those observed 
for miR-18a-5p and miR-16a-5p (Figure 5B). Macrophage-enriched miR-18a-5p was significantly upreg-
ulated as early as 2 days after IRI, and this was followed by miR-16-5p upregulation at 2 weeks (Figure 
6D). Conversely, PT cell–enriched miR-194-5p was significantly decreased from 7 days onward (Figure 6D). 
Although this observation of  reduced miR-194 in IRI was consistent with previously published data (7), 
miR-194 appeared to be a poor early marker of  tubular injury because it was unable to detect the significant 
ATN observed at day 2 (Figure 6, A and D). The dynamic profile of  the expression of  these miRNAs in IRI 
bore remarkable similarity to those observed in the R-UUO bulk expression (Figure 5C).
Figure 3. MiRNAs with consistent specific cell enrichment. MiRNAs demonstrating consistent cell type enrichment 
across all 4 experimental conditions are presented (n = 129). Each column represents a sample, each row a miRNA, and the 
color the relative expression (z score). Heatmap produced using unsupervised clustering by Euclidian distances. This data 
set can be fully explored at http://www.kidney-enriched-micrornas.com/. UUO, unilateral ureteric obstruction; R-UUO, 
reversal of UUO; Cell, cell origin from FACS; Cluster, assigned enrichment group.
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DEmiRNAs in human renal disease exhibit cell type enrichment. We next wished to determine whether 
cell-specific miRNAs identified in the R-UUO model are implicated in human renal injury. We hypothe-
sized that the application of  miRNA enrichment profiles to external bulk sRNA-Seq data sets from patients 
with kidney disease could increase our understanding of  the potential cellular origin of  the reported 
DEmiRNAs. To do this, we profiled the relative expression of  each cell-specific miRNA from our data set 
and crossed this with differentially expressed miRNAs in renal biopsies, from patients with kidney disease 
(Figure 7, Supplemental Table 2, and Supplemental Figure 12).
We first analyzed the renal miRNA transcriptional changes in human delayed graft function (DGF). 
DGF is typically the first clinical manifestation of  IRI occurring following renal transplantation and histo-
logically is associated with tubular injury and inflammatory cell infiltrates, including macrophages (33, 34). 
Correspondingly, we identified an upregulation of  macrophage-enriched miRNAs (e.g., miR-18a, miR-16) 
(Figure 7A) when probing the reported DEmiRNAs in DGF.
As diabetic nephropathy (DN) is a leading cause of  chronic kidney disease (CKD), we sought to exam-
ine the cellular origin of  reported DEmiRNAs. We found that miRNAs which were upregulated in kid-
ney biopsies from patients with DN (mean estimated glomerular filtration rate [eGFR] 33 mL/min/1.73 
m2) compared with controls (eGFR 101 mL/min/1.73 m2), corresponded to macrophage-enriched 
Figure 4. Global expression changes of cell-enriched miRNAs in the bulk and single-population data sets with injury and repair. (A) The cumu-
lative distribution of the highly enriched miRNA expression changes (log fold change, LogFC) in the kidney tissue sRNA-Seq data set is shown. 
There is an increase in macrophage-enriched (Mac, green line) and PDGFR-β+ (red line) and decrease in proximal tubular cell–enriched (PT, blue 
line) miRNAs’ expression versus nonenriched miRNAs (purple line) in comparisons against sham (sham vs. UUO day 7 and sham vs. R-UUO) (ECs 
in pink). This is in keeping with the histology. (B) When comparing the macrophage-enriched miRNA expression in the bulk versus single-popula-
tion Mac sRNA-Seq data sets, there was an upregulation of Mac enriched miRNAs within the bulk data set at UUO day 7 (vs. sham and UUO day 2) 
but not within the cells themselves. This suggests that the bulk changes may be due to changes in cellular proportions in the sample. (C) For PT 
cell–enriched miRNAs, there was a loss of expression both within the PT cells and to a greater extent the bulk tissue at UUO day 7 (vs. UUO day 2 
and R–UUO). Upon reversal, PT cell–enriched miRNA expression increased within PT cells to a relatively greater extent than was evident in the bulk. 
empirical cumulative distribution function plots for all cell types and comparisons are shown in Supplemental Figures 7–9. Kolmogorov-Smirnov 
test was used to compare the distribution of the LogFC. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.
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miRNAs (e.g., miR-16, miR-146b) and PDGFR-β+–enriched miRNAs (e.g., miR-199a-3p, miR-214-3p), 
with downregulated miRNAs mapping to PT cell–enriched miRNAs (Figure 7B and ref. 11). This is in 
keeping with the known inflammatory component of  DN, where the intensities of  the infiltrates are pro-
portional to the rate of  subsequent decline in renal function and tubular loss (15). Similarly, in human 
polycystic kidney disease — a genetic cause of  CKD where healthy tubules are replaced with cysts (10, 
35) — the predominant differences are that downregulated miRNAs mapped to the PT-enriched miR-
NAs (miR-192, miR-194, miR-30 family members), while upregulated miRNAs mapped again to macro-
phage-enriched miRNAs (e.g., the proinflammatory miR-324) (Figure 7C and refs. 10, 36). In addition, 
upregulation of  PDGFR-β+–enriched miRNAs (e.g., miR-199a) was observed, in keeping with the impli-
cated role of  myofibroblasts in polycystic kidney disease cyst progression (10, 37).
Macrophage-enriched miR-18a-5p and -16-5p are early urinary biomarkers of  delayed graft function. Having 
demonstrated differential expression of  miR-18a-5p and miR-16-5p in the kidney of  our IRI model and 
in external data sets of  human renal disease, we next wished to assess whether these miRNAs could be 
detected noninvasively. As a clinical model of  acute kidney injury with a significant ischemic etiological 
component, we studied urine samples from patients with DGF following renal transplantation. DGF is 
common following deceased donor renal transplantation (38), and the ability to both detect the extent of  
ischemic injury and predict the likely tempo of  recovery would be valuable in tailoring the management of  
these patients in the early posttransplant period. In order to maximize the potential clinical translation for 
a point-of-care urinary miRNA test, we employed total urinary RNA quantification after the removal of  
cellular debris, rather than analysis of  individual components, such as urinary exosomes. We hypothesized 
that changes in macrophage and PT cell–enriched miRNAs from the kidney would be both detectable and 
differentially expressed when measured in the urine of  patients with DGF.
Fifteen patients had urine samples available for analysis: 8 (53.3%) of  the patients received kidneys 
from donors after brainstem death (DBD), and 7 donated kidneys (46.7%) were from donors after circu-
latory death (DCD) (Table 3). There was no significant difference in donor or recipient characteristics, 
including age, sex, preoperative dialysis, and cause of  kidney failure, on univariate analysis. The 30-day and 
90-day renal function posttransplant was similar between groups (Table 3). Patients with DGF trended to 
having increased macrophage (CD68) number on the study protocol biopsy at day 5 (Figure 8A).
Although there was no significant difference in the urinary levels of  neutrophil gelatinase-associat-
ed lipocalin (NGAL) (Figure 8B) or KIM-1 (Figure 8C), a significant upregulation in miR-16-5p (fold 
change 11.3, P = 0.016) and miR-18a-5p (fold change 6.57, P = 0.011) was evident in the first-passed 
urine of  patients who developed DGF versus those with primary function (Figure 8D). No significant 
change in PT cell–enriched miR-194-5p was noted. Macrophage-enriched miRNAs demonstrated a 
high discrimination for the prediction of  DGF: miR-16-5p (AUC: 87%, CI: 67.9% to 100%) and miR-
18a-5p (AUC: 88.9%, CI: 71.3% to 100%) (Figure 8E). MiR-194-5p was a relatively poor predictor of  
DGF (AUC: 66.7%, CI: 36.6% to 96.72%) (data not shown). The best model performance was achieved 
Table 2. Temporal profile of DEmiRNAs within each data set
Temporal profile EC Mac PDGFR-β+ PT
Up in early injury 0 7 0 7
Up in late injury 22 52 137 52
Up throughout injury 8 65 6 65
Down in reversal 13 1 27 1
Down in early injury 0 2 2 2
Down in late injury 14 41 35 41
Down throughout injury 0 22 1 22
Up in reversal 11 3 31 3
Up in injury, down in reversal 1 7 4 7
Down in injury, up in reversal 0 4 10 4
Other profile 171 9 19 9
No significant changes 380 381 257 381
Profiles of miRNAs expressed within each data set with injury and reversal. This includes all miRNAs, enriched and nonenriched miRNAs.
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Figure 5. Selected enriched miRNA biomarkers’ expression and localization in the R-UUO model. (A) Expression of macrophage-enriched miR-18a-5p 
and miR-16-5p and proximal tubular cell–enriched miR-194-5p in the sorted cell populations from the R-UUO model demonstrating their enrichment 
for specific populations. (B) Localization of miRNA expression by in situ hybridization on R-UUO 3 μM FFPE sections using specific LNA double-labeled 
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by using the combination of  miR-16-5p and miR-18a-5p (AUC: 92.6%, CI: 79.3% to 100%). The indi-
vidual addition of  NGAL or KIM-1 to these macrophage-enriched miRNAs did not improve the pre-
diction of  the miRNAs.
Discussion
Understanding the cell specificity of  miRNAs’ expression in the kidney is key to unlocking their full poten-
tial as therapeutic targets and biomarkers. In this study, we first performed sRNA-Seq on 4 key renal types 
isolated from the kidney during health, injury, and repair. This foundation allowed us to apply a poten-
tially novel bioinformatic pipeline, establishing miRNA cell-specific enrichment and the consistency of  
that enrichment throughout renal injury and repair. Applied to murine models, our cell-enriched miRNAs 
mirrored the renal histology. Furthermore, we were able to deduce the likely cellular origin of  DEmiRNAs 
in bulk sample analyses from external data sets of  human kidney disease. Using this data-driven approach, 
we then rationally identified miRNAs with potential as biomarkers of  macrophage expression, finding 
miR-16 and miR-18a to be consistent markers when translated into another preclinical model of  kidney 
injury, the IRI model. In humans, we then demonstrated that miR-16 and miR-18a are promising urinary 
markers of  early acute kidney injury following renal transplantation. Finally, we made the data freely avail-
able through our interactive platform, providing a reference atlas for researchers in the field (http://www.
kidney-enriched-micrornas.com).
A number of  studies have previously reported kidney-enriched miRNAs, predominantly by microarray 
profiling of  different organs from normal animals. In the original microarray analysis, Sun et al. identified 
miRNAs -192, -194, -204, -215, and -216 as kidney specific when compared with heart, spleen, muscle, and 
prostate (16). Other miRNAs, such as miR-30b, -30c, -30d, -10a, and -192 and the miR-200 family, have 
also been suggested to be kidney specific (39). However, other studies have shown that these miRNAs are 
expressed in different tissues — for example, miR-192 is expressed in liver hepatocytes (40) — and that they 
play a role in other conditions, such as cancer (41, 42). Our data suggest this enrichment in the kidney may 
reflect the cellular makeup of  the kidney. We note that the miR-30 family, miR-192, and miR-194 (but not 
miR-10) are enriched in PT cells, which make up the largest cellular component of  the kidney. Correspond-
ingly, in whole-tissue sRNA-Seq, the PT cell–derived miRNAs dominate the expression observed and likely 
obscure changes in other cell types. MiR-192, -194, and -203 have previously been shown to be enriched in the 
cortex versus the medulla, consistent with PT specificity. However, the miR-200 family, which were proximal 
tubule enriched in our analysis, have previously been described as medullary enriched (43). Thus, a caveat of  
our approach is that it may not be capable of  discriminating between different portions of  the nephron, as 
some miRNAs may be expressed throughout the EC compartment at differing relative abundance.
A key strength in our approach over other studies is that it does not assume that miRNAs that are 
enriched in healthy animals will remain specific despite the transcriptomic changes evoked during injury and 
repair. In fact, in our study only 31.6% of  enriched miRNAs maintained cell-specific enrichment. This affects 
our mechanistic understanding of  the cellular origin of  miRNA when comparing control versus injury using 
bulk transcriptomics. Our stringent approach has resulted in overlap with other studies, offering support for 
their enrichment findings. For example, data from Lorenzen et al. described miR-24 as being endothelial 
enriched (44), a finding supported by our study. Furthermore, we confirm that the PDGFR-β+–enriched 
miRNAs described by Nakagawa and colleagues — including miR-214-3p, -199a-5p, and -199a-3p — are 
highly PDGFR-β+–enriched in our data set (45). Interestingly, the miR-21 family appeared highly enriched 
in macrophages in our analyses. Thus, the relatively consistent observation of  raised miR-21 with renal inju-
ry (46–48) could in part be related to inflammatory cell infiltrates when examining bulk renal samples. The 
ability to scrutinize the relative miRNA abundance in each cell type using this data set is an advantage over 
lengthy in situ staining procedures to assess the cellular origin of  miRNAs.
Our discovery of  miR-16-5p and 18a-5p as potential urinary biomarkers of  DGF is a potentially unique 
finding. These miRNAs have been described before in the kidney and other cell types. MiR-18a-5p has 
been shown to be upregulated in rat IRI kidney and downregulated in the whole blood (49). In addition to 
probes demonstrating a tubular pattern of expression for miR-194-5p and specific tubulointerstitial cellular expression for miR-16-5p and miR-18a-5p. 
(C) Comparisons of enriched miRNA expression with injury and repair in the matched single-population, renal cortex, and FACS cell proportions for 
macrophage-enriched miR-16-5p and miR-18a-5p and PT cell–enriched miR-194-5p. The cortical expression profile of the miRNAs mirrors the corre-
sponding enriched cell type proportions of the sorted kidney. All data are expressed as the median ± 1.5 IQR.
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Figure 6. Expression of selected enriched miRNAs in IRI. For the IRI model C57BL/6 mice underwent unilateral renal artery occlusion, resulting in warm 
ischemia for 18 minutes, followed by reperfusion and recovery for 2–21 days. (A) IRI mice demonstrated significant acute tubular necrosis on H&E staining 
at 2 and 7 days after injury. Scale bar: 50 μm. Data are expressed as median ± min and max value. One-way ANOVA with Tukey’s multiple-comparison 
test, ****P < 0.0001. (B) The normal renal architecture was progressively disrupted with significant fibrosis formation (semiquantified using picrosirius 
red staining) evident after 2 weeks. Scale bar: 50 μm. Data are expressed as median ± min and max value. ANOVA test with Tukey’s multiple-comparison 
test, *P < 0.05, **P < 0.01, ****P < 0.0001. (C) This injury was accompanied by increased macrophage number (F4/80 staining) as compared with sham 
animals. Scale bar: 50 μm. Data are expressed as median ± min and max value. ANOVA test with Tukey’s multiple-comparison test, *P < 0.05, **P < 0.01. 
(D) Within the kidney, we noted an upregulation of macrophage-enriched miR-16-5p and miR-18a-5p and downregulation of PT cell–enriched miR-194-5p 
with injury. Data expressed as mean ± SEM. ANOVA test with Tukey’s multiple-comparison test. *P < 0.05, **P < 0.01, ***P < 0.001, *****P < 0.00001.
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being biomarkers of  disease, they may be therapeutic targets. Overexpression of  miR-16 in models of  ath-
erosclerosis has been reported to reduce proinflammatory macrophage cytokine release, such as IL-6, while 
promoting the expression of  antiinflammatory IL-10 (50). Conversely in the liver, miR-18a induces an M1 
proinflammatory macrophage status (51). Our finding of  a reduction in miR-194 in the kidney following 
IRI is in keeping with findings from Godwin et al. (7). They believed their signature to be independent of  
infiltrating cells by showing this to be maintained in Ro/cγ0– deficient mice that lack NK cells, B cells, and T 
cells. In future, larger prospective clinical studies with multivariate regression modeling would be required 
to determine the accuracy and generalizability of  these miRNA markers when applied to DGF or non–
transplant-associated acute kidney injury, where there is a clinical need for improved markers.
Our approach, although comprehensive for the technology available, is limited to 4 cell types as is dictated 
by the FACS technology. While we chose to focus on cell types known to play a critical role in renal injury, we 
acknowledge other cell types do play a role. At present single-cell miRNA technology remains limited in its scope 
compared with scRNA-sequencing for mRNA. It is often limited to characterizing a small number of miRNAs, 
which may introduce more bias (52, 53). More recently, a half-cell single-cell sequencing approach has been uti-
lized by Wang et al. (54). However, this method was very low-throughput, precluding its use in in vivo modeling 
of kidney disease. In future, should scRNA-sequencing technology become practical for in vivo profiling of the 
miRNAs in the kidney, our study will provide an invaluable reference to aid in miRNA cluster classification.
In summary, in this study we define the cellular specificity of  miRNAs in the normal, injured, and 
repairing kidney. We demonstrate that consistent cell enrichment during injury and repair is observed only 
for selected miRNAs. We were able to apply this knowledge to unravel the cellular origin of  DEmiRNAs 
in bulk kidney samples and rationally select macrophage-enriched miRNAs as urinary acute kidney injury 
biomarkers. Future studies could expand our findings and add various other cell types, which could be 
integrated to generate a full sRNA-Seq atlas of  the kidney in injury and repair.
Figure 7. Cell specificity of DEmiRNAs in discrete human renal disease phenotypes. Cell-average expression in each cell type of DEmiRNAs in published human 
disease data sets: (A) delayed graft function (DGF) after renal transplantation, (B) diabetic nephropathy (DN), and (C) adult polycystic kidney disease (APKD) 
versus study controls. Mean expression values of miRNAs for each cell type across all conditions were calculated from our sRNA-Seq data. MiRNAs with high 
enrichment are shown here. Full plots of all DEmiRNAs and details of the data sets used are available in Supplemental Table 2 and Supplemental Figure 12.
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Methods
Murine models
All protocols and surgical procedures were performed following approval of  and in accordance with the 
local animal care committee and Animal Scientific Procedures Act 1986.
R-UUO model. The R-UUO procedure was performed as previously described (20). Male 8- to 12-week-
old C57BL/6 mice (Envigo) (n = 5/group) underwent laparotomy and distal ureteric dissection. To induce 
UUO, the ureter was ligated twice with 6/O silk suture distally, close to the bladder. A silastic tube was 
placed around the proximal ureter to prevent excessive dilatation, which would impede ureteric reimplan-
tation for the R-UUO group. In the R-UUO group, the ureter proximal to the ligature was reimplanted into 
the bladder following 7 days of  obstruction (UUO). Mice were culled at day 2 after UUO (UUO-2), at day 
7 after UUO (UUO-7), and in the R-UUO group at 7, 14, or 21 days after reversal by exsanguination under 
terminal isoflurane anesthesia. Based on data from previous experiments, we determined that n = 5/group 
was sufficient to provide 80% power to detect 20% difference in the degree of  renal fibrosis between groups, 
but we performed sequencing on n = 4 animals that had the closest to mean KIM-1/Havcr1 expression.
IRI model. Male C57BL/6 mice (8–10 weeks old, Envigo) underwent laparotomy, renal vascular pedicle 
exposure, and unilateral renal artery occlusion (ischemia) for 18 minutes followed by reperfusion. Culls were 
performed at 2, 7, and 14 days following IRI (n = 8 per group). Sham animals similarly underwent renal ped-
icle exposure without arterial clamping and were culled at matched time points (n = 4 per group). Based on 
pilot data from previous experiments, we determined this was sufficient to provide 90% power to detect 25% 
difference in the degree of  renal fibrosis between sham and IRI groups. At the termination of  an experiment, 
mice were culled under isoflurane terminal anesthesia and confirmed using cervical dislocation.
Kidney tissue processing
After culling, a thoracolaparotomy was performed, the right atrium was punctured, and 5 mL saline was 
infused via a left ventricular puncture in order to flush the kidneys prior to renal harvesting. Kidneys were 
divided into segments and either processed immediately (e.g., for FACS experiments), snap frozen, and 
Table 3. The donor and recipient characteristics of the renal transplant cohort
Characteristics No DGF DGF P
Donor type DBD 3 (37.5) 5 (62.5) 1.000
DCD 3 (42.9) 4 (57.1)
Donor age Mean (SD) 48.2 (9.8) 44.9 (17.4) 0.685
Donor sex Male 5 (45.5) 6 (54.5) 0.905
Female 1 (25.0) 3 (75.0)
Cold ischemic time Mean (SD) 584.7 (134.8) 704.7 (304.6) 0.385
Recipient age Mean (SD) 50.2 (14.3) 54.2 (17.7) 0.652
Recipient sex Male 2 (33.3) 4 (66.7) 1.000
Female 4 (44.4) 5 (55.6)
Cause of ESRF APKD 1 (33.3) 2 (66.7) 0.566
FSGS 2 (66.7) 1 (33.3)
Glomerulonephritis 1 (100.0)
Other 2 (33.3) 4 (66.7)
Diabetes 1 (100.0)
Reflux disease 1 (100.0)
Preoperative dialysis No 1 (50) 1 (50.0) 1.000
Yes 5 (38.5) 8 (61.5)
eGFR — 30 days Mean (SD) 51.5 (16.6) 38.9 (20.3) 0.228
eGFR — 90 days Mean (SD) 54 (12.8) 44.1 (15.2) 0.213 
Continuous variables are presented as mean and SD; categorical variables are presented as number and percentage with and without DGF. DBD, donation 
after brain death; DCD, donation after cardiac death; ESRF: end-stage renal failure; APKD, adult polycystic kidney disease.
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Figure 8. Macrophage-enriched miRNAs 16-5p and 18a-5p are differentially expressed in the urine of renal transplant 
recipients with DGF. (A) On the day 5 renal biopsy, increased macrophage (CD68-positive) cell number was observed in 
recipients with DGF versus those with PF (n = 2). Data are expressed as median ± min and max value. (B–D) The first 
available urine sample passed after transplantation was analyzed. No significant difference was seen in urinary injury 
markers (B) neutrophil associated gelatinase lipocalin (NGAL) or (C) KIM-1. (D) Macrophage-enriched miR-16-5p and 
miR-18a-5p were increased in recipients developing DGF; miR-194 was unchanged. Data are expressed as median ± min 
and max value. (E) Receiver operating characteristics curve of the differentially expressed miR-16-5p (AUC: 87%) and 
miR-18a-5p (AUC: 88.9%). Urinary miRNAs were normalized to miR-Cel-39 spike in D. Data reported as mean ± SEM. 
Mann-Whitney U test (*P < 0.05). PF, primary function.
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stored at –80°C or fixed in either 10% formalin (MilliporeSigma) to produce FFPE blocks or IHC zinc 
fixative for ZnFPE (BD Biosciences). Fixed samples were subsequently placed into 70% ethanol prior to 
being embedded in paraffin blocks.
Histology
FFPE or ZnFPE kidney blocks were cut into 3 μm sections. H&E staining was performed on FFPE sec-
tions. Sections were rehydrated and stained with hematoxylin (MilliporeSigma) for 5 minutes and washed 
in running tap water. Slides were dipped in 1% acid alcohol, washed in tap water then Scott’s tap water, 
and then counterstained in eosin solution (MilliporeSigma). Picrosirius red staining was performed on dep-
araffinized and rehydrated FFPE sections. Slides were stained with Picro-Sirius Red Solution (ab150681, 
Abcam) in the dark for 60 minutes. Slides were rinsed twice with acetic acid solution, dehydrated with 
100% ethanol, and mounted. For the F4/80 staining, 3 μm ZnFPE blocks were deparaffinized and rehy-
drated. Antigen unmasking was performed using citric acid (10 mM citric acid, 0.05% Tween-20, pH 6.0). 
Slides were blocked for endogenous peroxide with 0.2% H2O2, loaded in Sequenza racks (Thermo Fisher 
Scientific), and rinsed with PBS. Endogenous avidin and biotin were blocked with Avidin/Biotin Blocking 
Kit (Thermo Fisher Scientific). Slides were further blocked in Trident Universal Protein Block (GeneTex, 
Insight Biotechnology). Primary antibody (F4/80, clone BM8, ab16911, Abcam) was incubated at 1:100 
overnight at 4°C. After incubation slides were washed with PBS and biotinylated goat anti-rat (Vector Lab-
oratories, 2BScientific Ltd) at 1:200 diluted in antibody diluent (Vector Laboratories). Slides were washed 
and incubated with ABC Elite (Vector Laboratories), then DAB + (Agilent Technologies). Slides were then 
counterstained with Harris Haematoxylin (MilliporeSigma), then dehydrated through ethanol gradient and 
mounted with Pertex (MilliporeSigma).
In situ hybridization for miRNA localization
FFPE kidney blocks were cut into 3 μm sections. Sections were baked at 60°C overnight and then dep-
araffinized and rehydrated. In situ hybridization was carried out using miRCURY LNA miRNA probes 
(Qiagen) for miR-194-5p, miR-16-5p, and miR-18-5p and a control scramble probe. All probes were 5′, 3′ 
FAM labeled, and in situ was carried out as described in the miRCURY LNA miRNA ISH Optimization 
Kits (FFPE) handbook with the following changes. Following rehydration sections were antigen unmasked 
using 10 mM sodium citrate buffer, washed, and incubated with 0.1% Triton X-100 PBS for 10 minutes 
and washed prior to proteinase K treatment. The probes were hybridized overnight at hybridization Tm 
RNA and the NBT-BCIP solution left on for 5 hours. Images were taken on an ECLIPSE Ci-L bright-field 
microscope (Nikon) and the DS-L4 imaging program.
Kidney digestion for FACS. Immediately after culling, mice were perfused with 5 mL PBS. The kidneys 
were harvested, with the renal capsule removed and placed in ice-cold PBS. Equivalent kidney sections were 
finely minced in digest buffer (4.25 mg/mL Collagenase V from MilliporeSigma, 6.25 mg/mL Collagenase 
D from Roche, 10 mg/mL Dispase from Thermo Fisher Scientific, and 300 μg/mL DNase from Roche in 
RPMI 1640 with 10% FCS from Thermo Fisher Scientific, with 1% penicillin/streptomycin/l-glutamine 
from Thermo Fisher Scientific) prior to homogenization in gentle MACS C-tubes using the gentle MACS 
dissociator (Miltenyi Biotec). Samples were incubated at 37°C with shaking to maximize digestion. The 
kidney suspension was subjected to a second gentle MACS homogenization and digestion neutralized with 
an equal volume of  FACS buffer (PBS, 2 mM EDTA, and 2% FCS). Kidney cell suspensions were then 
sequentially passed through 100 μm, 70 μm, and 40 μm sieves. Any residual RBCs were lysed by RBC lysis 
buffer (MilliporeSigma). Cells were resuspended in ice-cold FACS buffer ready for use.
Fluorescence-activated cell sorting. Cell suspensions were incubated with FC block (BD Biosciences) and 
subsequently incubated with preconjugated antibodies in a round-bottomed plate. Controls were set up 
including unstained cells, beads with single stains of  each antibody, and fluorophore minus one. DAPI 
(MilliporeSigma) (1:1000) was added to samples immediately prior to acquisition to assess cell viability. 
Cells were sorted for 4 positive cell type populations (PT [LTL], Mac [F4/80], endothelial [CD31], and 
fibroblast [PDGFR-β] using antibodies detailed in Table 4.
RNA extraction methods
RNA extraction from FACS populations. Following FACS, cells were sorted into RLT buffer (Qiagen) at room tem-
perature. RNA was extracted using RNeasy Micro Kit (Qiagen), which has been amended for miRNA extraction. 
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Briefly, cells were homogenized by vortexing for 10 seconds; the lysate was pipetted onto a gDNA Elim-
inator spin column and centrifuged at 10,000g for 30 seconds. The gDNA column was discarded and 1.5 
times volume molecular grade pure ethanol was added to the lysate and placed on an RNeasy MinElute 
column. The column was spun at 10,000g for a further 30 seconds, 700 mL RWT buffer was added, and the 
extraction continued as per manufacturer’s protocol.
RNA extraction from tissue. Total RNA from cortical kidney tissue was obtained using the miRNeasy kit 
(Qiagen) following the manufacturer’s instructions. Tissue was lysed using 700 mL QIAzol and homoge-
nized with steel beads (Qiagen) using Tissue Lyser II (Qiagen) for 1 minute.
RNA extraction from urine. RNA was extracted using the miRNeasy Mini Kits (Qiagen) with the follow-
ing modification to the manufacturer’s instructions; 750 mL of  QIAzol lysis reagent was added along with 
1 mg carrier RNA (MS2 RNA, Roche). For normalization of  the sample, synthetic Caenorhabditis elegans 
cel-miR-39 (MC10956, cel-miR-39; Qiagen) was spiked in to achieve a final concentration of  0.5 pM. 
Thereafter the miRNeasy manufacturer’s instructions were followed (46).
RNA-sequencing. RNA integrity was checked using Agilent Technologies nanochips. All samples utilized 
for sRNA-Seq had a minimum RNA integrity score of 7. For the single-population sRNA-Seq, RNA under-
went sRNA-Seq by Genewiz, using the Illumina HiSeq platform, generating paired-end reads of 150 bp (n = 4 
per group). For the whole-tissue sRNA-Seq, RNA underwent sRNA-Seq by Genewiz, using the Illumina HiS-
eq 2500 platform, generating single-end reads of 50 bp performed over 2 runs (n = 4 per group). The sequenc-
ing data are deposited with the National Center for Biotechnology Information’s Gene Expression Omnibus 
database, accession number GSE150035.
Bioinformatics analysis
Alignment and preprocessing. Raw reads were examined for quality control by FastQC. Raw reads were 
trimmed using TrimGalore (Ver 0.4.1)/ Cutadapt (version 1.1) to remove primer/adaptor contamination 
and low-quality reads (<20 Phred score). Clean, high-quality, trimmed reads as confirmed by FastQC were 
aligned to the mouse genome GRCm38 and MiRBase (Ver 22) using the Bowtie wrapper Shortstack (55), 
achieving a mapping rate of  72% to 86% in the single-population sRNA-Seq. Alignment rates between 
cell types and experimental conditions were similar. This provided a count table of  miRNA reads ready 
for downstream analysis in Rstudio (Ver 3.6.1). The pipeline for the whole-tissue sRNA-Seq was as above, 
except the 2 runs of  the sequencing were merged before entering the pipeline. For preprocessing, the R 
package edgeR was employed to generate counts per million, lowly expressed reads were removed, and 
normalization for library size was performed (56).
Differential expression. Exploratory principal component analyses were performed using DESeq2 (Version 
1.24.0) (57). This revealed sample 68c was a significant outlier (PDGFR-β group, UUO-7), and as such this 
sample was removed from all downstream analyses (Supplemental Figure 1B), leaving 3 samples for this 
group. Otherwise for each cell type and condition, there were 4 samples per group. Differential expression 
analysis was performed on normalized counts principally using EdgeR (Version 3.26.8) (56). EdgeR uses a 
negative binomial distribution to model miRNA reads in deep sequencing data sets. A fold change > 1.5 and 
FDR (Benjamini-Hochberg method) < 0.05 were considered significant. Data are freely available at http://
www.kidney-enriched-micrornas.com. Clusters of  dynamic expression within each cell type were curated by 
generating logical arguments based on the differential expression analysis (Supplemental Table 3). Within this 
Table 4. Antibodies used for flow cytometry
Antibody name Catalog number Company  
(lot number)
Final dilution
PDGFR-β (PE) 136006 BioLegend (B257631) 1:50
CD31 (Bright Violet 605) 102427 BioLegend (B240043) 1:100
F4/80 (PE CY7) 25480182 eBioscience, Thermo Fisher 
Scientific (4281123)
1:100
LTL (FITC) FL1321 Vector Laboratories (ZC0914) 1:200
CD45 (APC) 30-F11 BD Biosciences (511919) 1:100
Antibodies used for FACS sorting the cells, fluorochromes, dilutions used, antibody clones, and lot numbers.
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system, a miRNA could not exist in multiple clusters. Validated gene targets of enriched miRNAs were identified 
using the R package multimiR (Version 1.6.0), which searches “mirecords,” “mirtarbase,” and “tarbase” (58).
Cell enrichment clustering. Unbiased fuzzy clustering was performed for each experimental condition using the 
R package mFuzz (Version 2.44) (24) on normalized counts. This approach has the advantage of being more 
robust to noise and allows the global clustering structure to be visualized. A membership value of 1.18 and 16 
clusters was utilized based on the protocol guidelines. Clusters that demonstrated an increased expression in 
a single cell type for more than 2 samples were selected as potential enriched clusters and taken forward. This 
process was repeated until mFuzz cell type clusters for sham, UUO-2, UUO-7, and R-UUO were obtained.
A limitation of  fuzzy clustering in the context of  identifying a cell-specific miRNA is that a miRNA 
could exist in multiple clusters. Therefore, in order to improve cell specificity, this unbiased fuzzy clustering 
was combined with selecting miRNAs based on their relative cell type expression. For each condition, the 
mean cell type–specific z score of  an individual miRNA was calculated, and miRNAs with a z score more 
than 1.15 were considered cell type enriched by this approach. The z score represents the number of  SDs 
the expression of  a miRNA in a sample is away from the mean of  all the values for the same miRNA. The 
z score is equal to: (log[sample miRNA expression] – mean[log(miRNA expression)])/SD. This cutoff  was 
selected because, at this level of  stringency, stable cell type clusters were evident when the data were reclus-
tered using agglomerative hierarchical clustering by Euclidian distances (using pHeatmap, Version 1.0.12).
MiRNAs enriched using both approaches were taken forward as cell-enriched markers for each time 
point. MiRNAs that demonstrated enrichment for more than one cell type were considered Not Cell Spe-
cific. Enrichment consistency was considered low, moderate, or high based on the number of  experimental 
conditions (out of  4) the miRNA demonstrated cell type enrichment (1, 2–3, 4, respectively).
Enrichment comparisons in external data sets. We wished to explore the likely cellular origin of  DEmiRNAs 
published in murine and human renal diseases identified from predominantly high-throughput approaches. 
We gave preference to studies which (a) were in humans, (b) were published recently, and (c) had data avail-
able within the supplementary materials or deposited on GEO2R.
Many of  the studies encompassed microarray data and older studies where the nomenclature of  
miRNAs had changed or where the miRNA strand information was not available. In addition, there are 
considerable inconsistencies in between the nomenclature of  murine and human miRNA annotation. 
To address this, we first employed the R package miRBaseConverter (Version 1.8.0) (59) to determine 
the annotation of  the external data set and convert it to the latest miRBase version (version 22) as used 
in our study. For the human to mouse miRNA annotation matching, we obtained the species-specific 
mature miRNA sequences from miRbase (60). We then matched the murine to human sequences on the 
basis of  the same seed sequence (nucleotides 2 to 7) and similarity of  miRNA name. This generated 476 
miRNAs with a unique seed sequence and miRNA name paired for mouse and human that were used for 
annotation merging of  the data sets.
Human subjects
Analysis was performed on stored samples from renal transplant recipients previously recruited to a clin-
ical trial (ClinicalTrials.gov NCT01430156) investigating delayed graft function (61). The full details of  
the study are as reported by Thomas et al. (61). We included patients recruited to the placebo arm of  this 
trial who had urine samples stored and available for analysis. DGF was defined as “increased or stable 
serum creatinine, or a decrease of  less than 10% per day for 3 consecutive days in the first week after 
transplantation” (61). We took advantage of  measurements of  urinary KIM-1 (ng/mL) and NGAL (ng/
mL), which had been quantified by ELISA, and normalized these measurements to urinary creatinine to 
correct for differences in urinary dilution. Renal biopsies were obtained and studied as part of  the trial on 
day 5 following transplant. Renal macrophages were identified by immunofluorescence using anti-CD68 
antibody (ab13243, Abcam). The number of  macrophages was quantified by counting CD68-positive cells 
in 8 nonoverlapping fields at ×20 magnification on a ZEISS LSM 710 confocal microscope.
Urinary samples and miRNA measurements
Urine samples were obtained on day 0 (day of  transplant) and days 1, 2, 3, and 5 posttransplant if  available. 
Urine samples were stored at –80°C for further analysis. Following collection, urine samples were stored 
at –80°C. Samples were defrosted and centrifuged at 2000g for 10 minutes at 4°C to remove any cellular 
debris. The top 350 mL was taken as the sample and RNA extracted as described above.
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MiRNA and gene expression analysis
FACS-sorted cells were collected for 4 positive cell populations. cDNA was synthesized from 750 pg of  
template RNA using the Ovation RNA Seq V2 (Nugen) amplification as per manufacturer’s instructions. 
Gene expression was assessed by qRT-PCR using the PerfeCTa FastMix II probe master (VWR) and 
TaqMan Gene Expression assays (Life Technologies, Thermo Fisher Scientific) and normalized to hypox-
anthine-guanine phosphoribosyltransferase (HPRT Mm00446968_m1).
For quantitative real-time PCR analysis of  gene expression, cDNA was synthesized from 1 µg of  tem-
plate RNA, using the QuantiTect Reverse Transcription Kit (Qiagen). Quantitative PCR was performed 
using the PerfeCTa FastMix II probe master (VWR) and TaqMan Gene Expression Assay–specific primers 
(Life Technologies, Thermo Fisher Scientific) for Havcr1 (Mm00506686_m1) and normalized to hypoxan-
thine-guanine phosphoribosyltransferase (HPRT Mm00446968_m1).
For quantitative real-time PCR analysis of  miRNA expression, reverse transcription of  total RNA 
was performed with Applied Biosystems TaqMan MicroRNA Reverse Transcription Kit (Life Technol-
ogies, Thermo Fisher Scientific), followed by quantitative PCR using Universal Mastermix II (no UNG) 
(Life Technologies, Thermo Fisher Scientific) and specific miRNA assays (miR-18a-5p 002422, miR-16-5p 
000391, miR-194-5p 000493, U6 001973).
Normalization was to endogenous U6 and exogenous spike miR-cel-39 for the analysis of  murine kid-
ney and human urine samples, respectively. The relative quantification of  miRNA differential expression 
was calculated using the 2−ΔΔCT method.
Statistics
Statistical analyses were performed using either GraphPad Prism 8.0 or specific packages within R (3.6.1) 
for more complex analyses. Two independent samples were compared using the Mann-Whitney U test.
For 3 or more independent samples, 1-way ANOVA was used, and when equality of  variances could 
not be ensured, Welch’s 1-way ANOVA was substituted. Adjustments for multiple testing were included 
using the Tukey or Dunnett methods as appropriate, and all tests were 2 tailed.
Receiver operating characteristics were calculated using the R package pROC (Version 1.16.2) (62). To 
assess the prediction of  urinary miRNAs in combination, a multivariable binomial logistic regression mod-
el was performed in R using the glm wrapper finalfit (Version 1.0.1). Kolmogorov-Smirnov tests were used 
to compare the probability distribution curves of  the global log fold changes of  enriched miRNAs. All other 
statistical analyses performed as part of  the sRNA-Seq analysis are outlined in the corresponding sections.
A statistical probability P < 0.05 was considered significant. Significance is depicted as follows: *P < 
0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001.
Study approval
Murine models. All protocols and surgical procedures were performed following approval and in accor-
dance with the local animal care committee at the University of  Edinburgh and the Animal Scientific 
Procedures Act 1986.
Human participants. With approval from the trial team and study sponsor Academic and Clinical Cen-
tral Office for Research and Development, analysis was performed on biobank samples collected as part of  
the clinical trial (ClinicalTrials.gov NCT01430156) (61) in accordance with the Declaration of  Helsinki. 
Written informed consent was received from participants prior to inclusion in the trial, including the use of  
samples for further research. The full details of  the study are as reported by Thomas et al. (61).
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